In Brief: Angeion
This article was originally published in The Gray Sheet
Angeion: Company resumes U.S. clinical implants of its Sentinel series of implantable cardioverter defibrillators immediately following FDA sign-off on Jan. 26, the firm states. The company had temporarily suspended implants of the Sentinel series, including 2000, 2010, 2011 and 2012 models, in November 1997 following five incidents in which battery voltage depleted prematurely due to a defective capacitor ("The Gray Sheet" Nov. 17, I&W-3). To correct the problem, Angeion changed its manufacturing process to incorporate a new capacitor component, and the firm has modified the monitoring schedule for patients implanted with the ICDs. Angeion filed a premarket approval application for the devices in June 1997 that is currently under review ("The Gray Sheet" June 23, In Brief)...
You may also be interested in...
The director of adult immunizations at Johns Hopkins International Vaccine Access Center talks to Scrip about undertaking a massive COVID-19 vaccination effort in the US.
P&G’s oral care business drove 35% of total category market growth in the firm’s fiscal 2020 and exemplifies its growth strategy for all segments – grow entire categories rather than take competitors’ market share, says CFO Jon Moeller.
The Pink Sheet explains the procedures underpinning the UK’s emergency use authorization of the Pfizer/BioNTech COVID-19 vaccine.